Expert consensus on treatment for stage III non‐small cell lung cancer

Autor: Yi‐Long Wu, Shun Lu, Qinghua Zhou, Li Zhang, Ying Cheng, Jie Wang, Buhai Wang, Chengping Hu, Lizhu Lin, Wenzhao Zhong, Yong Song, Nong Yang, Xiaorong Dong, Jian Zhao, Haihong Yang, Hui Guo, Xiaolong Yan, Hongxu Liu, Rui Ma, Jie Lin, Siyang Liu, Chun Chen, Lifeng Wang, Chengzhi Zhou, Ming Zhou, Fang Wu, Xue‐Ning Yang, Yingying Du, Yu Yao, Yang Shao, Shaodong Hong, Jiuwei Cui, Xueping Quan, Rongrong Chen, Jiayan Wu, Jiatao Zhang, Jianya Zhou, Binchao Wang, Chao Cheng, Huijuan Wang, Jingjing Liu, Lin Wu, Yan Huang, Yukun Kuang, Yongchang Zhang, Jia Hu, Jinji Yang, Weineng Feng, Wenmei Su, Yun Fan, Fan Yang, Ming Chen, Kejing Tang, Yi Pan, Peng Shen, Anwen Liu, Haibo Zhang, Wenhua Liang, Qing Zhou, Zhiyong Ma, Xiuyu Cai, Hui Liu, Longfei Chen, Shaokun Chuai, Jianzhen Shan, Yanfang Zheng, Changxuan You, Xiaoxia Zhu, Li Li, Tongmei Zhang, Haiyan Tu, Wurong Lin, Xuchao Zhang, Penghui Zhou, Zunfu Ke, Huiying Liang

Publikováno v: Medicine Advances, Vol 1, Iss 1, Pp 3-13 (2023)

Abstract Stage III non‐small cell lung cancer (NSCLC) encompasses a group of diseases with high heterogeneity. Such patients should actively receive comprehensive treatments. It is imperative for all stage III NSCLC patients to receive consultation

Externí odkaz: https://doaj.org/article/628a61c2e0b7401888cbceb96adb32ce

Imperatorin Targets MCL-1 to Sensitize CD133+ Lung Cancer Cells to γδ-T Cell-Mediated Cytotoxicity

Autor: Changxuan You, Yu Yang, Beili Gao

Publikováno v: Cellular Physiology and Biochemistry, Vol 49, Iss 1, Pp 235-244 (2018)

Background/Aims: CD133+ cancer cells display low sensitivity to anti-cancer treatment; thus, combination treatment with adjuvant drugs is required to improve the efficiency of cancer therapy. The aim of this study was to explore the effect of imperat

Externí odkaz: https://doaj.org/article/a27f605a2c9846038ae3776424f229d6

Overexpression of Testes-Specific Protease 50 (TSP50) Predicts Poor Prognosis in Patients with Gastric Cancer

Autor: Fang Liu, Qinghua Cao, Ni Liu, Changzhao Li, Changxuan You, Chuanxin Liu, Ling Xue, Rongcheng Luo

Publikováno v: Gastroenterology Research and Practice, Vol 2014 (2014)

Purpose. To investigate the expression of TSP50 protein in human gastric cancers and its correlation with clinical/prognostic significance. Methods. Immunohistochemistry (IHC) analysis of TSP50 was performed on a tissue microarray (TMA) containing 33

Externí odkaz: https://doaj.org/article/d07267ead5994c4789b02c78a8feebd5

Expression of miR-21 and miR-138 in colon cancer and its effect on cell proliferation and prognosis

Autor: Changxuan You, Xuewu Huang, Qi Xu, Bo Shen, Xuelong Jiao, Liming Jin

Publikováno v: Oncology Letters

Effect of miR-21 and miR-138 on the proliferation of colon cancer cells and their association with prognosis were investigated. Expression levels of miR-21 and miR-138 in colorectal cancer and normal adjacent tissues were compared. Differential expre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd32ea5d4baf6dd0f7f848fadf953077
http://europepmc.org/articles/PMC6341732

PALB2 mutation as a predictive biomarker for immunotherapy in patients with advanced melanoma: Results from (a pooled analysis of) five multicenter, randomized clinical trials

Autor: Changxuan You, Mengli Huang, Yating Zheng

Publikováno v: Journal of Clinical Oncology. 39:e21537-e21537

e21537 Background: PALB2, a gene in the homologous recombination repair (HRR) pathway, has been shown to be associated with the efficacy of platinum based chemotherapy, and PARP inhibitor therapy in breast, prostate, ovarian, and pancreatic cancers.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f683b41c973e126fa11cd53aafc19815
https://doi.org/10.1200/jco.2021.39.15_suppl.e21537